Disclosed is the use of a nicotinic acetylcholine receptor agonist for treating or inhibiting the development or progression of a visual disorder, including a visual disorder of the posterior segment of the eye, such as myopia.
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
An apparatus for making combined vestibular and somatosensory function assessments, comprising: a portable base unit comprising: a movable platform being at least partially rotatable about an axis of rotation; in use, a user stands with both feet on the movable platform; an adjustable stopping mechanism for adjusting an extent to which the movable platform can rotate in at least one direction with respect to a horizontal plane; and a controller for controlling the adjustable stopping mechanism to selectively adjust the extent to which the movable platform is rotated by one of a plurality of discrete measurable amounts based on a control signal; a visual occlusion headset worn by the user, the headset comprising a device for recording a vestibular function response in response to a vestibular function test.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
Uses of dopamine, deuterated dopamine, a deuterated dopamine derivative such as deuterated L-dopa, or a pharmaceutically acceptable salt thereof, in inhibiting the development or progression of visual disorders, such as myopia, or a visual disorder associated with diabetic retinopathy or Parkinson's disease, are provided.
An apparatus for making combined vestibular and somatosensory function assessments, comprising: a portable base unit comprising: a movable platform being at least partially rotatable about an axis of rotation; in use, a user stands with both feet on the movable platform; an adjustable stopping mechanism for adjusting an extent to which the movable platform can rotate in at least one direction with respect to a horizontal plane; and a controller for controlling the adjustable stopping mechanism to selectively adjust the extent to which the movable platform is rotated by one of a plurality of discrete measurable amounts based on a control signal; a visual occlusion headset worn by the user, the headset comprising a device for recording a vestibular function response in response to a vestibular function test.
Pharmaceutical ocular compositions include levodopa, an antioxidant and an aqueous carrier. A wide selection of antioxidants can be included in the compositions, such as ascorbic acid, phenolic acids, sorbic acid, sodium bisulfite, sodium metabisulfite, acetyl cysteine, sodium thiosulfate, ethylene diamine tetraacetic acid, sodium nitrite, ascorbyl stearate, ascorbyl palmitate, alpha-thioglycerol, erythorbic acid, cysteine hydrochloride, citric acid, tocopherol or vitamin E, tocopherol acetate, dibutylhydroxytoluene, soybean lecithin, sodium thioglycolate, butylhydroxyanisole, propyl gallate, uric acid, melatonin, and thiourea, as well as salts and combinations of these antioxidants.
A frame piece adapted for assembly with a matching frame piece to form a beehive frame includes: a first side spaced from a second side by a pair of end struts, the first side having at least one frame coupling portion that is releasably engageable with at least one corresponding frame coupling portion of the matching frame piece; wherein, when the frame piece is assembled with the matching frame piece, the at least one frame coupling portion cooperates with the at least one corresponding frame coupling portion to form a hinge or hinges about which the frame piece is foldable relative to the matching frame piece.
Uses of dopamine, deuterated dopamine, a deuterated dopamine derivative such as deuterated L-dopa, or a pharmaceutically acceptable salt thereof, in inhibiting the development or progression of visual disorders, such as myopia, or a visual disorder associated with diabetic retinopathy or Parkinson's disease, are provided.
e.g.e.g., nucleus, cytoplasm, cell membrane) of a cancer cell, for predicting the likelihood of response of a cancer cell to therapy including immunotherapy, for stratifying a cancer patient as a likely responder or non-responder to a therapy, for managing treatment of a cancer patient, and for predicting clinical outcomes.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
Disclosed are proteinaceous molecules corresponding to an acetylation site and their use for inhibiting or reducing the nuclear localization of a nuclear localizable polypeptide, such as PD-1, PD-L1 and PD-L2. This invention also relates to the use of the proteinaceous molecules for altering at least one of (i) formation; (ii) proliferation; (iii) maintenance; (iv) epithelial to mesenchymal cell transition (EMT); or (v) mesenchymal to epithelial cell transition (MET) of a PD-1-, PD-L1- or PD-L2-overexpressing cell, and for treating or preventing a cancer in a subject.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
The present invention relates to a composition for enhancing T-cell function or for treating a T-cell dysfunctional disorder, the composition comprising, consisting or consisting essentially of a lysine specific demethylase (LSD) inhibitor (which may be a MAO inhibitor or phenelzine) and a Programmed cell death protein- 1 (PD-1) binding antagonist (which may be an antibody, preferably nivolumab, pembrolizumab, lambrolizumab or pidilizumab).
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Disclosed are compositions comprising levodopa and an antioxidant for inhibiting the development or progression of visual disorders inclusive of visual disorders associated with diabetic retinopathy or Parkinson's disease, and myopia.
The present invention discloses the use of protein kinase C (PKC-θ) inhibitors for enhancing the immune effector function of functionally repressed T-cells that have undergone epithelial to mesenchymal transition (EMT). In specific embodiments, PKC-θ inhibitors are disclosed for use in enhancing susceptibility of exhausted T-cells to reinvigoration by PD-1 binding antagonists. The compositions of the present invention find utility in treating a range of disorders including T-cell dysfunctional disorders such as pathogenic infections and hyperproliferative disorders.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
Disclosed are lysine specific histone demethylase-1 (LSD1) inhibitors in methods and compositions for immune checkpoint inhibition. The invention also relates to proteinaceous molecules and their use in altering at least one of (i) formation, (ii) 5 proliferation, (iii) maintenance, (iv) epithelial to mesenchymal cell transition (EMT), or (v) mesenchymal to epithelial cell transition (MET) of an LSD1 overexpressing cell.
The present invention relates to a nanoparticle composition comprising one or more β-triketones selected from leptospermone, isoleptospermone, grandiflorone and flavesone, together with a carrier.
Disclosed are compositions comprising levodopa and an antioxidant for inhibiting the development or progression of visual disorders inclusive of visual disorders associated with diabetic retinopathy or Parkinson's disease, and myopia.
Disclosed are proteinaceous molecules and their use in conditions associated with PKC-θ overexpression, such as cancer. More particularly, the present invention discloses proteinaceous molecules and their use in altering at least one of (i) formation; (ii) proliferation; (iii) maintenance; (iv) epithelial to mesenchymal cell transition; or (v) mesenchymal to epithelial cell transition of a PKC-θ overexpressing cell.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Disclosed are compositions and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of LSD- and/or PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.
Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.
Disclosed are compositions and methods that use lysine demethylase inhibitors for inhibiting the growth of cancer stem cells or tumor initiating cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer5 cells and/or for preventing cancer recurrence.
This invention discloses recombinant hepatitis delta viral (HDV) vectors that are useful inter alia in the treatment or prevention of hepatitis virus infections. The viral vectors are predicated on the stable integration of heterologous nucleic acid sequences into a HDV genome, which confer a substantially rod-like secondary structure on the resulting recombinant HDV genome.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
brevets
